ERBB2 and breast carcinoma: Subgroup analyses of trials involving HER2+ breast cancer patients, as well as clinical trials specifically designed to identify the optimal treatment strategy for HR+/HER2+ breast cancer, can help guide treatment decisions (17, 18).